Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Kezar Life Sciences Inc (KZR) today. The company’s shares closed yesterday at $4.49, close to its 52-week low of $4.12.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.9% and a 46.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rhythm Pharmaceuticals Inc.
Currently, the analyst consensus on Kezar Life Sciences Inc is a Strong Buy with an average price target of $15, implying a 234.1% upside from current levels. In a report issued on July 29, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
Based on Kezar Life Sciences Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $7.64 million. In comparison, last year the company had a GAAP net loss of $6.78 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs.